PFM Health Sciences LP Has $5.87 Million Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)

PFM Health Sciences LP raised its position in Keros Therapeutics, Inc. (NASDAQ:KROS) by 203.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 101,050 shares of the company’s stock after purchasing an additional 67,695 shares during the quarter. PFM Health Sciences LP’s holdings in Keros Therapeutics were worth $5,868,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. acquired a new position in Keros Therapeutics in the second quarter valued at about $1,118,000. Bank of New York Mellon Corp boosted its position in Keros Therapeutics by 18.8% in the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after buying an additional 18,755 shares in the last quarter. SG Americas Securities LLC acquired a new position in Keros Therapeutics in the second quarter valued at about $532,000. American Century Companies Inc. lifted its position in shares of Keros Therapeutics by 24.9% during the second quarter. American Century Companies Inc. now owns 298,170 shares of the company’s stock worth $13,626,000 after purchasing an additional 59,364 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS opened at $57.74 on Friday. The company’s 50 day simple moving average is $59.49 and its 200 day simple moving average is $52.30. Keros Therapeutics, Inc. has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The firm has a market capitalization of $2.34 billion, a P/E ratio of -11.08 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same period in the previous year, the firm earned ($1.33) earnings per share. The business’s quarterly revenue was up 4750.0% on a year-over-year basis. Sell-side analysts expect that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Guggenheim assumed coverage on shares of Keros Therapeutics in a research report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price on the stock. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating on the stock. Wedbush reiterated an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.